Xiaobo Xia

Xiaobo Xia

Auto-generated profile, based on publicly available information

Xiaobo Xia

Novartis Biomedical Research, Cambridge, Massachusetts

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2026 in Cancer Research
Verified
Journal Article
Open access
JLJinxiu Li
Jinxiu Li
MNMary L. Nelson
Mary L. Nelson
LLLi Li
Li Li
XXXiaobo Xia
Xiaobo Xia
CSChristine Stephan
Christine Stephan
KJKevin B Jones
Kevin B Jones
Synovial sarcoma incorporates the SS18::SSX fusion oncoprotein into GLTSCR1-containing BRG1/BRM and associated factors (GBAF) complexes, which confers a dependency on the GBAF subunit BRD9. However, synovial sarcoma clinical trials with multiple BRD9 degraders failed to achieve clinically impactful remissions. In this study, we identified a mechanistic framework to explain these results. BRD9 depletion served to blunt proliferation in synovial sarcoma harboring minimal genomic alterations, rare in trial participants. In cultured cells, xenografts, and recombinant-purified complexes, BRD9 loss did not affect GBAF assembly. Although BRD9 degradation in synovial sarcoma reduced GBAF enrichment at target loci, BRD9-less complexes maintained or increased chromatin accessibility and associated gene transcription. Biochemical assays with purified recombinant GBAF demonstrated increased nucleosome sliding in the absence of BRD9. Together, these findings show that BRD9 restrains GBAF activity, with BRD9 degradation increasing enzymatic remodeling and target gene expression by fusion oncoprotein–distributed GBAFs in synovial sarcoma. This subtle epigenetic disturbance creates a low hurdle for synovial sarcoma to surpass, limiting the therapeutic efficacy of BRD9 degraders. Significance: BRD9 represses the GBAF chromatin remodeling complex, which causes enhanced rather than disrupted SS18::SSX complex activity following BRD9 degradation and explains the lack of efficacy of pharmacological BRD9 degraders in synovial sarcoma.

27 January 2023 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
GWGregg Wildenberg
Gregg Wildenberg
DMDeborah J. Mariner
Deborah J. Mariner
PAPanos Z. Anastasiadis
Panos Z. Anastasiadis
MDMicheal A. Davis
Micheal A. Davis
RIRenee Ireton
Renee Ireton
MDMichael Dohn
Michael Dohn
Albert (Al) B. Reynolds, professor of cancer biology, Vanderbilt School of Medicine, died unexpectedly, and far too soon, at his home in Nashville, TN, at the a

15 September 2026
Verified
Other
Open access
JLJinxiu Li
Jinxiu Li
MNMary L. Nelson
Mary L. Nelson
LLLi Li
Li Li
XXXiaobo Xia
Xiaobo Xia
CSChristine Stephan
Christine Stephan
KJKevin B Jones
Kevin B Jones
Supplemental Figure S5 (associated with Figure 5). BRD9 depletion does not compromise GBAF assembly. A. Western blots of the middle-fractions of the glycerol gradient fractionated nuclear extracts from HS-SY-II cells exposed to DMSO or WA-68 in vitro. B. Western blots of the middle-fractions of the glycerol gradient fractionated nuclear extracts from STG048 PDXs exposed to vehicle control saline or WA-68 in vivo. C. Western blots of transfected BioID2 with a V5 tag fused either to the carboxy or amino terminus of BRD9 in the HD-MY-Z cell line, demonstrating doxycycline induction of expression of the fused proteins. D. Mass spectrometry proteomics showing the fold-change (FC) relative abundance of biotinylated proteins in BRD9::BioID2::V5 vs. BioID2::V5::BRD9 transfected HD-MY-Z cells after doxycycline or control (purple dots indicate significance in both experiments.

15 September 2026
Verified
Other
Open access
JLJinxiu Li
Jinxiu Li
MNMary L. Nelson
Mary L. Nelson
LLLi Li
Li Li
XXXiaobo Xia
Xiaobo Xia
CSChristine Stephan
Christine Stephan
KJKevin B Jones
Kevin B Jones
Supplemental Figure S1 (associated with Figure 1). BRD9 depletion arrests proliferation in SyS. A. Western blot indicating depletion efficiency for BRD9 by four doxycycline inducible shRNAs in the human 12733/99 SyS cell line. B. Cell viability after 12 days in culture for shBRD9 versus shControl by doxycycline induction in 12733/99. C. Colony formation assays of 12733/99 cells at 12 days following BRD9 depletion versus control. D. Western blot indicating depletion efficiency for BRD9 by four doxycycline inducible shRNAs in the human HS-SY-II SyS cell line. E. Cell viability after 12 days in culture for shBRD9 versus shControl by doxycycline induction in HS-SY-II. F. Colony formation assays of HS-SY-II cells following BRD9 depletion versus control for 12 days. G. RTqPCR relative expression of SS18::SSX in HS-SY-II cells subjected to four shRNAs directed against the junctional sequence of the fusion oncogene, or two controls. H. Western blot indicating depletion efficiency for SS18::SSX1 by four doxycycline inducible shRNAs and two controls in the human HS-SY-II SyS cell line. I. Cell viability after 12 days in culture for shSS18::SSX versus shControls by doxycycline induction in HS-SY-II. J. Colony formation assays of HS-SY-II cells following SS18::SSX depletion versus control (same as in F). K. Colony formation assays of negative control OVCAR-4 cells following BRD9 depletion versus positive and non-targeted control shRNAs. L. Photomicrographs of Ki-67 immunohistochemistry (ICH) of SYO-1 xenograft samples after treatment with doxycycline or control for non-targeted BRD9 directed shRNAs. M. Western blots showing BRD9 depletion efficiency at indicated time points for in vivo dox-inducible shBRD9 in xenografted HS-SY-II cells. N. Western blots showing BRD9 depletion efficiency at indicated time points for in vivo dox-inducible shBRD9 in xenografted SYO-1 cells.

15 September 2026
Verified
Other
Open access
JLJinxiu Li
Jinxiu Li
MNMary L. Nelson
Mary L. Nelson
LLLi Li
Li Li
XXXiaobo Xia
Xiaobo Xia
CSChristine Stephan
Christine Stephan
KJKevin B Jones
Kevin B Jones
Supplemental Figure S8 (associated with Figure 8). Increased GBAF remodeling in SyS increases H2AK119ub-associated transcription while paradoxically decreasing H2AK119ub enrichment. A. RNA-seq defined differential expression transcriptome wide following exposure of the ASKA, SYO-1, and HS-SY-II SyS cell lines to WA-68 versus DMSO control. B. Gene set enrichment analysis of the differentially expressed genes with the normalized enrichment score (NES) plotted for each tested KEGG Hallmark pathway.

15 September 2026
Verified
Other
Open access
JLJinxiu Li
Jinxiu Li
MNMary L. Nelson
Mary L. Nelson
LLLi Li
Li Li
XXXiaobo Xia
Xiaobo Xia
CSChristine Stephan
Christine Stephan
KJKevin B Jones
Kevin B Jones
Supplemental Figure S7 (associated with Figure 7). GBAF remodeler sliding activity increases in the absence of BRD9. A. RNA-seq defined differential expression comparing WA-68 exposure to control DMSO in a control set of maintained active transcription (MAT, expressed genes without fusion and H2AK119ub targeting) following BRD9 degradation in SYO-1 cells. B. Differential expression of sarcomagenesis silenced transcription (SST, not significantly expressed in vehicle treated cells) genes following BRD9 degradation or control in SYO-1 cells. C. Titration sliding assays showing slid and ejected fractions after 60 minutes at variable molar ratios of recombinant nucleosomes to recombinant GBAF with or without BRD9 omitted. Recombinant nucleosomes include H3.3A refers to histone H3.3 variant with C110A mutation introduced to avoid ubiquitin transfer to this residue. Titration assays on recombinant nucleosomes that bear H2A ubiquitination in the octamer show no effect on nucleosome sliding for GBAF wild-type or GBAF lacking BRD9. The absence of BRD9 increases the overall sliding by GBAF. D. Heatmaps and enrichment plots from ATAC-seq and ChIP-seq for GLTSCR1 and SS18::SSX (by HA-tag) at genome-wide distal ATAC-seq sites in the HS-SY-II cell line after exposure to control DMSO or 12, 24, 48, or 96 hours of WA-68 E. The same at loci defined a priori by distal co-localization of called peaks for H2AK119ub, GLTSCR1, and SS18::SSX, termed sarcomagenesis activated transcription (SAT) sites.